• LAST PRICE
    101.0100
  • TODAY'S CHANGE (%)
    Trending Down-0.8600 (-0.8442%)
  • Bid / Lots
    100.9500/ 8
  • Ask / Lots
    101.0700/ 8
  • Open / Previous Close
    101.3600 / 101.8700
  • Day Range
    Low 100.8800
    High 101.5500
  • 52 Week Range
    Low 98.6000
    High 134.6300
  • Volume
    257,064
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 101.87
TimeVolumeMRK
09:32 ET1828101.295
09:33 ET182282101.25
09:35 ET26477101.01
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMRK
Merck & Co Inc
258.2B
21.2x
-43.23%
United StatesNVS
Novartis AG
240.6B
18.9x
-5.59%
United StatesPFE
Pfizer Inc
157.3B
37.1x
-7.10%
United StatesAZN
AstraZeneca PLC
221.3B
32.4x
+17.52%
United StatesABBV
AbbVie Inc
354.1B
69.3x
-6.05%
United StatesRHHBY
Roche Holding AG
256.5B
20.4x
+3.28%
As of 2024-11-05

Company Information

Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.

Contact Information

Headquarters
126 East Lincoln AvenueRAHWAY, NJ, United States 07065
Phone
908-740-4000
Fax
908-423-1987

Executives

Chairman of the Board, President, Chief Executive Officer
Robert Davis
Chief Financial Officer, Executive Vice President
Caroline Litchfield
Chief Human Resource Officer
Betty Larson
Executive Vice President, Chief Information and Digital Officer
David Williams
Executive Vice President, General Counsel, Corporate Secretary
Jennifer Zachary

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$258.2B
Revenue (TTM)
$63.2B
Shares Outstanding
2.5B
Dividend Yield
3.05%
Annual Dividend Rate
3.0800 USD
Ex-Dividend Date
09-16-24
Pay Date
10-07-24
Beta
0.42
EPS
$4.77
Book Value
$14.84
P/E Ratio
21.2x
Price/Sales (TTM)
4.1
Price/Cash Flow (TTM)
21.4x
Operating Margin
21.64%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.